Nucleic acid therapeutics: Concepts for targeted delivery to solid tumors

Therapeutic Delivery

Volumn 1, Issue 1, 2010, Pages 91-107

  Ogris, Manfred ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; ADENOVIRUS VECTOR; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; DIPHTHERIA TOXIN; DOXORUBICIN; DRUG CARRIER; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GOLNERMINOGENE PRADENOVEC; IODINE 131; LIPOPLEX; LIPOSOME; MESSENGER RNA; MICRORNA; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; ONCOLYTIC VIRUS; ONYX 015; PACLITAXEL; PLASMID DNA; POLYCATION; POLYETHYLENEIMINE; POLYINOSINIC POLYCYTIDYLIC ACID; RETROVIRUS VECTOR; SMALL INTERFERING RNA; SODIUM IODIDE SYMPORTER; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNINDEXED DRUG; VIRUS VECTOR;

BIOCOMPATIBILITY; BLADDER CANCER; BREAST CARCINOMA; CANCER GENE THERAPY; CANCER RADIOTHERAPY; CYSTIC FIBROSIS; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; DRUG RETENTION; DRUG SELECTIVITY; DRUG TARGETING; ENZYMATIC DEGRADATION; EX VIVO GENE TRANSFER; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HYPERTHERMIC THERAPY; IMMUNE DEFICIENCY; LEUKOPENIA; LIGAND BINDING; LIPOSOMAL DELIVERY; LIVER CELL CARCINOMA; LIVER INJURY; LUNG CARCINOMA; MACROMOLECULE; MOLECULAR WEIGHT; MOLECULARLY TARGETED THERAPY; NEUROBLASTOMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PLASMA CLEARANCE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RNA INTERFERENCE; SOLID TUMOR; THYROID CANCER; TOXICITY TESTING; TUMOR MODEL; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

EID: 79955035352     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.10.9     Document Type: Review

References (114)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100(1), 57-70 (2000). (Pubitemid 30046295)
2. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29(6 Suppl. 16), 15-18 (2002).
3. Apostolopoulos C, Castellano L, Stebbing J, Giamas G. Bendamustine as a model for the activity of alkylating agents. Future Oncol. 4(3), 323-332 (2008). (Pubitemid 351984083)
4. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 3(5), 330-338 (2003). (Pubitemid 37328853)
5. Gascoigne KE, Taylor SS. How do anti-mitotic drugs kill cancer cells? J. Cell. Sci. 122(15), 2579-2585 (2009).
6. Baguley BC. Multidrug resistance in cancer. Methods Mol. Biol. 596, 1-14 (2009).
7. Drablos F, Feyzi E, Aas PA et al. Alkylation damage in DNA and RNA-repair mechanisms and medical significance. DNA Repair (Amst.) 3(11), 1389-1407 (2004). (Pubitemid 39221738)
8. Klein S, McCormick F, Levitzki A. Killing time for cancer cells. Nat. Rev. Cancer 5(7), 573-580 (2005). (Pubitemid 40942833)
9. Riely GJ. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J. Thorac. Oncol. 3(6 Suppl. 2), S146-S149 (2008). (Pubitemid 351786747)
10. Klein S, Levitzki A. Targeting the EGFR and the PKB pathway in cancer. Curr. Opin. Cell Biol. 21(2), 185-193 (2009).
11. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 11(17-18), 812-818 (2006). (Pubitemid 44280021)
12. Torchilin VP. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 9(2), E128-E147 (2007).
13. Hilger RA, Richly H, Grubert M et al. Pharmacokinetics (PK) of a liposomal encapsulated fraction containing doxorubicin and of doxorubicin released from the liposomal capsule after intravenous infusion of Caelyx/Doxil. Int. J. Clin. Pharmacol. Ther. 43(12), 588-589 (2005). (Pubitemid 43009360)
14. Twelves CJ, Dobbs NA, Aldhous M, Harper PG, Rubens RD, Richards MA. Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer. Cancer Chemother. Pharmacol. 28(4), 302-307 (1991).
15. Verschraegen CF, Skubitz K, Daud A et al. A Phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 63(5), 903-910 (2009).
16. Aghi M, Hochberg F, Breakefield XO. Prodrug activation enzymes in cancer gene therapy. J. Gene Med. 2(3), 148-164 (2000).
17. Lo HW, Day CP, Hung MC. Cancer-specific gene therapy. Adv. Genet. 54, 235-255 (2005).
18. Kelly EJ, Russell SJ. MicroRNAs and the regulation of vector tropism. Mol. Ther. 17(3), 409-416 (2009).
19. Sahu NK, Shilakari G, Nayak A, Kohli DV. Antisense technology: a selective tool for gene expression regulation and gene targeting. Curr. Pharm. Biotechnol. 8(5), 291-304 (2007). (Pubitemid 47595838)
20. Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin. Cancer Res. 15(4), 1126-1132 (2009).
21. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391(6669), 806-811 (1998). (Pubitemid 28099681)
22. Leung RK, Whittaker PA. RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol. Ther. 107(2), 222-239 (2005). (Pubitemid 40910042)
23. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 8(2), 129-138 (2009).
24. Tiemann K, Rossi JJ. RNAi-based therapeutics - current status, challenges and prospects. EMBO Mol. Med. 1(3), 142-151 (2009).
25. Kaur H, Babu BR, Maiti S. Perspectives on chemistry and therapeutic applications of locked nucleic acid (LNA). Chem. Rev. 107(11), 4672-4697 (2007). (Pubitemid 350225863)
26. Plank C, Zauner W, Wagner E. Application of membrane-active peptides for drug and gene delivery across cellular membranes. Adv. Drug Deliv. Rev. 34(1), 21-35 (1998). (Pubitemid 28464476)
27. Blaese RM, Culver KW, Miller AD et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 270(5235), 475-480 (1995).
28. Cavazzana-Calvo M, Hacein-Bey S, De Saint BG et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288(5466), 669-672 (2000). (Pubitemid 30241569)
29. Hacein-Bey-Abina S, Garrigue A, Wang GP et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118(9), 3132-3142 (2008).
30. Ehrhardt A, Haase R, Schepers A, Deutsch MJ, Lipps HJ, Baiker A. Episomal vectors for gene therapy. Curr. Gene Ther. 8(3), 147-161 (2008).
31. Ivics Z, Izsvak Z. Transposons for gene therapy! Curr. Gene Ther. 6(5), 593-607 (2006). (Pubitemid 44524462)
32. Freimuth P, Philipson L, Carson SD. The coxsackievirus and adenovirus receptor. Curr. Top. Microbiol. Immunol. 323, 67-87 (2008).
33. Raper SE, Yudkoff M, Chirmule N et al. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum. Gene Ther. 13(1), 163-175 (2002). (Pubitemid 34075180)
34. Everts M, Curiel DT. Transductional targeting of adenoviral cancer gene therapy. Curr. Gene Ther. 4(3), 337-346 (2004). (Pubitemid 39162394)
35. Kreppel F, Gackowski J, Schmidt E, Kochanek S. Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors. Mol. Ther. 12(1), 107-117 (2005). (Pubitemid 40862362)
36. Kreppel F, Kochanek S. Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol. Ther. 16(1), 16-29 (2008).
37. Nemunaitis J, Edelman J. Selectively replicating viral vectors. Cancer Gene Ther. 9(12), 987-1000 (2002). (Pubitemid 35469142)
38. Wilson JM. Gendicine. The first commercial gene therapy product. Hum. Gene Ther. 16(9), 1014-1015 (2005). (Pubitemid 41324560)
39. Olins DE, Olins AL, Von Hippel PH. Model nucleoprotein complexes: studies on the interaction of cationic homopolypeptides with DNA 501. J. Mol. Biol. 24, 157-176 (1967).
40. Olins DE, Olins AL, Von Hippel PH. On the structure and stability of DNA-protamine and DNA-polypeptide complexes. J. Mol. Biol. 33, 265-281 (1968).
41. Shapiro JT, Leng M, Felsenfeld G. Desoxyribonucleic acid-polylysine complexes. Structure and nucleotide specifity. Biochemistry 8, 3219-3232 (1969).
42. Felgner PL, Gadek TR, Holm M et al. Lipofection. A highly efficient, lipid mediated DNA-transfection procedure. Proc. Natl Acad. Sci. USA 84, 7413-7417 (1987).
43. Konstan MW, Wagener JS, Hilliard KA et al. Single dose escalation study to evaluate safety of nasal administration of CFTR001 gene transfer vector to subjects with cystic fibrosis. Mol. Ther. 7, S386 (2003).
44. Hyde SC, Pringle IA, Abdullah S et al. Cpg-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat. Biotechnol. 26(5), 549-551 (2008). (Pubitemid 351668040)
45. Sidi AA, Ohana P, Benjamin S et al. Phase I/II marker lesion study of intravesical BC-819 DNA plasmid in H19 over expressing superficial bladder cancer refractory to Bacillus Calmette-Guerin. J. Urol. 180(6), 2379-2383 (2008).
46. Wang J, Sui M, Fan W. Nanoparticles for tumor targeted therapies and their pharmacokinetics. Curr. Drug. Metab. 11(2),129-41 (2010).
47. Torchilin VP. Passive and active drug targeting. Drug delivery to tumors as an example. Handb. Exp. Pharmacol. (197), 3-53 (2010).
48. Yotsumoto F, Sanui A, Fukami T et al. Efficacy of ligand-based targeting for the egf system in cancer. Anticancer Res. 29(11), 4879-4885 (2009).
49. Driessen WH, Ozawa MG, Arap W, Pasqualini R. Ligand-directed cancer gene therapy to angiogenic vasculature. Adv. Genet. 67, 103-121 (2009).
50. Gunther M, Wagner E, Ogris M. Specific targets in tumor tissue for the delivery of therapeutic genes. Curr. Med. Chem. Anticancer Agents 5(2), 157-171 (2005). (Pubitemid 40347989)
51. Pradhan P, Banerjee R, Bahadur D, Koch C, Mykhaylyk O, Plank C. Targeted magnetic liposomes loaded with doxorubicin. Methods Mol. Biol. 605, 279-293 (2010).
52. Tashjian JA, Dewhirst MW, Needham D, Viglianti BL. Rationale for and measurement of liposomal drug delivery with hyperthermia using non-invasive imaging techniques. Int. J. Hyperthermia 24(1), 79-90 (2008). (Pubitemid 351167621)
53. Li L, Ten Hagen TL, Schipper D et al. Triggered content release from optimized stealth thermosensitive liposomes using mild hyperthermia. J. Control. Release 143(2), 274-279 (2010).
54. Mackay JA, Chilkoti A. Temperature sensitive peptides. Engineering hyperthermia-directed therapeutics. Int. J. Hyperthermia 24(6), 483-495 (2008).
55. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specific targeting on the biodistribution and efficacy of sirna nanoparticles measured by multimodality in vivo imaging. Proc. Natl Acad. Sci. USA 104(39), 15549-15554 (2007). (Pubitemid 47502954)
56. Philipp A, Meyer M, Wagner E. Extracellular targeting of synthetic therapeutic nucleic acid formulations. Curr. Gene Ther. 8(5), 324-334 (2008).
57. Xenariou S, Griesenbach U, Ferrari S et al. Using magnetic forces to enhance non-viral gene transfer to airway epithelium in vivo. Gene Ther. 13(21), 1545-1552 (2006). (Pubitemid 44567151)
58. Berg K, Folini M, Prasmickaite L et al. Photochemical internalization: a new tool for drug delivery. Curr. Pharm. Biotechnol. 8(6), 362-372 (2007).
59. Falk MH, Issels RD. Hyperthermia in oncology. Int. J. Hyperthermia 17(1), 1-18 (2001). (Pubitemid 32058478)
60. Wust P, Hildebrandt B, Sreenivasa G et al. Hyperthermia in combined treatment of cancer. Lancet Oncol. 3(8), 487-497 (2002). (Pubitemid 34863670)
61. Karino T, Koga S, Maeta M. Experimental studies of the effects of local hyperthermia on blood flow, oxygen pressure and pH in tumors. Jpn. J. Surg. 18(3), 276-283 (1988).
62. Song CW, Park HJ, Lee CK, Griffin R. Implications of increased tumor blood flow and oxygenation caused by mild temperature hyperthermia in tumor treatment. Int. J. Hyperthermia 21(8), 761-767 (2005). (Pubitemid 41807103)
63. Hauck ML, Dewhirst MW, Bigner DD, Zalutsky MR. Local hyperthermia improves uptake of a chimeric monoclonal antibody in a subcutaneous xenograft model. Clin. Cancer Res. 3(1), 63-70 (1997). (Pubitemid 27079446)
64. Kong G, Braun RD, Dewhirst MW. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res. 60(16), 4440-4445 (2000). (Pubitemid 32103623)
65. Kong G, Dewhirst MW. Hyperthermia and liposomes. Int. J. Hyperthermia 15(5), 345-370 (1999). (Pubitemid 29425711)
66. Issels RD, Schlemmer M, Lindner LH. The role of hyperthermia in combined treatment in the management of soft tissue sarcoma. Curr. Oncol. Rep. 8(4), 305-309 (2006). (Pubitemid 43970982)
67. Chang E, Chalikonda S, Friedl J et al. Targeting vaccinia to solid tumors with local hyperthermia. Hum. Gene Ther. 16(4), 435-444 (2005). (Pubitemid 40647141)
68. Vekris A, Maurange C, Moonen C et al. Control of transgene expression using local hyperthermia in combination with a heat-sensitive promoter. J. Gene Med. 2(2), 89-96 (2000).
69. Madio DP, Van Gelderen P, Despres D et al. On the feasibility of MRI-guided focused ultrasound for local induction of gene expression. J. Magn. Reson. Imaging 8(1), 101-104 (1998). (Pubitemid 28099565)
70. Hoekstra D, Rejman J, Wasungu L, Shi F, Zuhorn I. Gene delivery by cationic lipids: in and out of an endosome. Biochem. Soc. Trans. 35(1), 68-71 (2007).
71. Behr JP. The proton sponge: a trick to enter cells the viruses did not exploit. Chimia 51(1-2), 34-36 (1997).
72. Cho YW, Kim JD, Park K. Polycation gene delivery systems: escape from endosomes to cytosol. J. Pharm. Pharmacol. 55(6), 721-734 (2003). (Pubitemid 36752715)
73. Ogris M, Brunner S, Schuller S, Kircheis R, Wagner E. Pegylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther. 6(4), 595-605 (1999). (Pubitemid 29192668)
74. Wightman L, Kircheis R, Rossler V et al. Different behavior of branched and linear polyethylenimine for gene delivery in vitro and in vivo. J. Gene Med. 3(4), 362-372 (2001). (Pubitemid 33691776)
75. Boussif O, Lezoualc'h F, Zanta MA et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl Acad. Sci. USA 92(16), 7297-7301 (1995).
76. Kircheis R, Kichler A, Wallner G et al. Coupling of cell-binding ligands to polyethylenimine for targeted gene delivery. Gene Ther. 4(5), 409-418 (1997). (Pubitemid 27226583)
77. Goula D, Benoist C, Mantero S, Merlo G, Levi G, Demeneix BA. Polyethylenimine-based intravenous delivery of transgenes to mouse lung. Gene Ther. 5(9), 1291-1295 (1998). (Pubitemid 28448439)
78. Finsinger D, Remy JS, Erbacher P, Koch C, Plank C. Protective copolymers for nonviral gene vectors. Synthesis, vector characterization and application in gene delivery. Gene Ther. 7(14), 1183-1192 (2000). (Pubitemid 30488765)
79. Clamme JP, Azoulay J, Mely Y. Monitoring of the formation and dissociation of polyethylenimine/DNA complexes by two photon fluorescence correlation spectroscopy. Biophys. J. 84(3), 1960-1968 (2003). (Pubitemid 36322958)
80. Boeckle S, von Gersdorff K, van der Piepen S, Culmsee C, Wagner E, Ogris M. Purification of polyethylenimine polyplexes highlights the role of free polycations in gene transfer. J. Gene Med. 6(10), 1102-1111 (2004). (Pubitemid 40228122)
81. Chollet P, Favrot MC, Hurbin A, Coll JL. Side-effects of a systemic injection of linear polyethylenimine-DNA complexes. J. Gene Med. 4(1), 84-91 (2002). (Pubitemid 40277159)
82. Ogris M. Nucleic acid based therapeutics for tumor therapy. Anticancer Agents Med. Chem. 6(6), 563-570 (2006). (Pubitemid 44697114)
83. Fahrmeir J, Gunther M, Tietze N, Wagner E, Ogris M. Electrophoretic purification of tumor-targeted polyethylenimine-based polyplexes reduces toxic side effects in vivo. J. Control. Release 122, 236-245 (2007). (Pubitemid 47404673)
84. Fischer D, Bieber T, Li Y, Elsasser HP, Kissel T. A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity. Pharm. Res. 16(8), 1273-1279 (1999). (Pubitemid 29393618)
85. Pack DW, Hoffman AS, Pun S, Stayton PS. Design and development of polymers for gene delivery. Nat. Rev. Drug Discov. 4(7), 581-593 (2005). (Pubitemid 40975711)
86. Kloeckner J, Wagner E, Ogris M. Degradable gene carriers based on oligomerized polyamines. Eur. J. Pharm. Sci. 29(5), 414-425 (2006). (Pubitemid 44709863)
87. Russ V, Elfberg H, Thoma C, Kloeckner J, Ogris M, Wagner E. Novel degradable oligoethylenimine acrylate ester-based pseudodendrimers for in vitro and in vivo gene transfer. Gene Ther. 15(1), 18-29 (2008). (Pubitemid 350269429)
88. Russ V, Gunther M, Halama A, Ogris M, Wagner E. Oligoethylenimine-grafted polypropylenimine dendrimers as degradable and biocompatible synthetic vectors for gene delivery. J. Control. Release 132(2), 131-140 (2008).
89. Klutz K, Russ V, Willhauck MJ et al. Targeted radioiodine therapy of neuroblastoma tumors following systemic nonviral delivery of the sodium iodide symporter gene. Clin. Cancer Res. 15(19), 6079-6086 (2009).
90. Schwerdt A, Zintchenko A, Concia M et al. Hyperthermia induced targeting of thermosensitive gene carriers to tumors. Hum. Gene Ther. 19(11), 1283-1292 (2008).
91. Zintchenko A, Ogris M, Wagner E. Temperature dependent gene expression induced by PNIPAM-based copolymers: potential of hyperthermia in gene transfer. Bioconjug. Chem. 17(3), 766-772 (2006). (Pubitemid 43794388)
92. Dreher MR, Simnick AJ, Fischer K et al. Temperature triggered self-assembly of polypeptides into multivalent spherical micelles. J. Am. Chem. Soc. 130(2), 687-694 (2008). (Pubitemid 351455582)
93. Shir A, Ogris M, Wagner E, Levitzki A. EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice. PLoS Med. 3(1), e6 (2006).
94. Takeda K, Akira S. Toll-like receptors. Curr. Protoc. Immunol. Chapter 14, Unit 14.12 (2007).
95. Salazar AM, Levy HB, Ondra S et al. Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study. Neurosurgery 38(6), 1096-1103; discussion 1103-1094 (1996).
96. Nakamura O, Shitara N, Matsutani M, Takakura K, Machida H. Phase I-II trials of poly(ICLC) in malignant brain tumor patients. J. Interferon Res. 2(1), 1-4 (1982). (Pubitemid 12118440)
97. Butowski N, Lamborn KR, Lee BL et al. A North American brain tumor consortium Phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J. Neurooncol. 91(2), 183-189 (2009).
98. Riesco-Eizaguirre G, Santisteban P. A perspective view of sodium iodide symporter research and its clinical implications. Eur. J. Endocrinol. 155(4), 495-512 (2006). (Pubitemid 44608424)
99. Smanik PA, Liu Q, Furminger TL et al. Cloning of the human sodium lodide symporter. Biochem. Biophys. Res. Commun. 226(2), 339-345 (1996). (Pubitemid 26331906)
100. Spitzweg C, Morris JC. Approaches to gene therapy with sodium/iodide symporter. Exp. Clin. Endocrinol. Diabetes 109(1), 56-59 (2001). (Pubitemid 32154892)
101. Barton KN, Stricker H, Brown Sl et al. Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate. Mol. Ther. 16(10), 1761-1769 (2008).
102. Kircheis R, Schuller S, Brunner S et al. Polycation-based DNA complexes for tumor-targeted gene delivery in vivo. J. Gene Med. 1(2), 111-120 (1999). (Pubitemid 129631068)
103. Klutz K, Russ V, Willhauck M et al. Comparison of two different non-viral gene delivery vectors for systemic sodium iodide symporter gene transfer in HCC. Hum. Gene Ther. 20(11), 1515-1515 (2009).
104. Roth JA (Ed.). Gene-Based Therapies For Cancer. Springer, Heidelberg, Germany (2010).
105. Freytag SO, Khil M, Stricker H et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 62(17), 4968-4976 (2002). (Pubitemid 34984421)
106. Weichselbaum RR, Kufe D. Translation of the radio- and chemo-inducible TNFerade vector to the treatment of human cancers. Cancer Gene Ther. 16(8), 609-619 (2009).
107. Davis ME. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol. Pharm. 6(3), 659-668 (2009).
108. Davis ME, Zuckerman JE, Choi CH et al. Evidence of RNAi in humans from systemically administered sirna via targeted nanoparticles. Nature 464(7291), 1067-1070 (2010).
109. Mayrhofer P, Schleef M, Jechlinger W. Use of minicircle plasmids for gene therapy. Methods Mol. Biol. 542, 87-104 (2009).
110. Klein-Marcuschamer D, Yadav VG, Ghaderi A, Stephanopoulos GN. De novo metabolic engineering and the promise of synthetic DNA. Adv. Biochem. Eng. Biotechnol. (2010) (Epub ahead of print).
111. Challenges in the process development of a novel Zero-CpG CFTR plasmid for human clinical use www.users.ox.ac.uk/~genemed/Publications/ pdf/HebelASGT08.pdf
112. Glucocorticoid modulation of nucleic acid-mediated immune stimulation www.freepatentsonline.com/ 20070054873.pdf
113. Clinicaltrials.gov - study NCT00393809 www.clinicaltrials.gov/ct2/show/ NCT00393809
114. Clinicaltrials.gov - study NCT00788307 www.clinicaltrials.gov/ct2/show/ NCT00788307